“Immune B Cells know it better”: tumorimmunological panel assay to define tumor-associated antigen binding antibodies in patients with metastatic melanomas

Background Revealing novel cancer targeting biomarkers is a great challenge, and especially urging in cancer types with a more pronounced metastatic feature. We focus on potential anti-tumor immune reactions of the host. In order to harness the natural humoral immune response a novel immunological and molecular genetic panel assay has been developed for the investigation of patients with melanomas.